Definitive Contract 75F40121C00131
Award Date
9/27/21
Potential Completion Date
3/26/25
Potential Value
$2.6M
Federal Agency
Food and Drug Administration
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Cambridge, MA 02139, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $6,038,686.00, was issued by the Food and Drug Administration (FDA) to the Massachusetts Institute of Technology (MIT) to generate a Broad Agency Announcement (BAA) addressing the ongoing growth in continuous manufacturing within cell lines. The requirement is being funded through the President's initiative to focus on advanced manufacturing. This is a definitive, firm-fixed-price contract with a period of performance through September 29, 2027. No...
This is a $4,999,325.00 federal contract awarded by the Food and Drug Administration (FDA) to the Massachusetts Institute of Technology (MIT) to conduct research on controlled protein capture via continuous crystallization and precipitation for monoclonal antibody manufacturing. The contract was awarded under the FDA's Broad Agency Announcement for Advanced Regulatory Science and does not have a set-aside designation. The contract involves research and development activities to advance...
This is a Definitive Contract awarded by the Food and Drug Administration (FDA) to the Massachusetts Institute of Technology (MIT) for the development of an integrated cGMP facility for mRNA manufacturing. The contract is valued at $82,182,000.00 and has a completion date of September 28, 2026. It is a Firm Fixed Price contract with no set-aside designation. MIT has subcontracted with The Pennsylvania State University and Rensselaer Polytechnic Institute to perform research related to mRNA...
This federal contract award is for BIOMEDICAL (APPLIED/EXPLORATORY) research and development work, with a ceiling value of $621,724.00. The contract was awarded by the U.S. government to the Massachusetts Institute of Technology (MIT) on April 1, 2009, with a planned completion date of December 31, 2009. The contract is part of the GENOMIC SEQUENCING CENTERS FOR INFECTIOUS DISEASES major program and is a definitive contract with a cost-no-fee pricing type. The work is being performed in...
This federal contract award, valued at $11,348,590.00, was issued by the National Institutes of Health (NIH) to the Massachusetts Institute of Technology (MIT) under an Other Transaction Agreement. The contract, titled "ARPA-H ADAPT AURORA: AI-DRIVEN UNDERSTANDING OF RESPONSE OPTIMIZATION AND RESISTANCE ASSESSMENT," is focused on advanced research and development in artificial intelligence and related technologies. The award does not have a set-aside designation, indicating MIT's broad...
This is a $978,324 definitive contract awarded by the Food and Drug Administration (FDA) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for a 2-year period ending in April 2025. The contract is to enhance the FDA's Source Model by incorporating and analyzing state and regional-level data. The contract was awarded under a Broad Agency Announcement (BAA) that solicits advanced research and development proposals to support FDA regulatory science...
This is a cost-plus-fixed-fee delivery order for $4,726,928.00 awarded by the Food and Drug Administration (FDA) to The Mitre Corporation, a non-profit organization that operates federally funded research and development centers. The contract is for research and technical support related to pathogen reduction technologies (PRT) for the FDA's Center for Biologics Evaluation and Research (CBER). The contract has no set-aside designation. The Mitre Corporation has extensive experience supporting...
This federal contract award is for the Bio-Mod program, which seeks to develop devices and techniques to produce multiple protein biologics in response to specific battlefield threats and medical needs. The prime contractor is the Massachusetts Institute of Technology (MIT), a premier private research university known for its advanced scientific and technological capabilities. The $24,851,563.00 contract does not have a set-aside designation, indicating MIT's broad competitiveness across...
The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response awarded a $700,000.00 firm fixed price definitive contract to the Massachusetts Institute of Technology (MIT) for the "MIT LANGER LAB 3D VACCINE PRINTER" project. This award is not associated with a set-aside program. The contract work is to be performed in Cambridge, MA and has an end date of August 31, 2022. The original solicitation was a Broad Agency Announcement (BAA) issued...
This federal contract award, valued at $4,835,002, was made by the Food and Drug Administration (FDA) to The Mitre Corporation, a not-for-profit organization that operates federally funded research and development centers. The contract is for system engineering and acquisitions support for the FDA's Office of Acquisitions and Grants Services (OAGS). This is a cost-plus-fixed-fee delivery order contract with a period of performance ending on September 29, 2017. The contract was not set aside...